S33005

S33005 is a serotonin–norepinephrine reuptake inhibitor (SNRI) that was under development by Servier for the treatment of depression and related disorders. It is structurally related to venlafaxine but has a more complex molecular structure. Venlafaxine appears to be a sigma modulator, but it is not known if S33005 shares this activity.
Wikipedia contributors, "S33005", Wikipedia, revision 1324499081, retrieved 20 November 2026, source, CC BY-SA 4.0.